Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.1818
+0.0057 (3.24%)
At close: Aug 11, 2026, 4:00 PM EDT
0.1815
-0.0003 (-0.17%)
After-hours: Aug 11, 2026, 5:48 PM EDT
Gossamer Bio Employees
As of December 31, 2025, Gossamer Bio had 162 total employees, including 161 full-time and 1 part-time employees. The number of employees increased by 17 or 11.72% compared to the previous year.
Employees
162
Change (1Y)
17
Growth (1Y)
11.72%
Revenue / Employee
$342,821
Profits / Employee
-$1,113,556
Market Cap
88.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 162 | 17 | 11.72% | 161 | 1 |
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Adicet Bio | 102 |
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| PolyPid | 75 |
| Biomea Fusion | 40 |
| NeurAxis | 24 |
| MAIA Biotechnology | 13 |
GOSS News
- 15 days ago - Gossamer Bio upgraded to Outperform from Market Perform at Leerink - TheFly
- 15 days ago - Gossamer Bio Transcript: Investor update - Transcripts
- 15 days ago - Gossamer Bio Press release: Investor update - Filings
- 15 days ago - Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights - TheFly
- 15 days ago - Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire
- 5 weeks ago - Gossamer Bio announces determination of conversion rate for senior secured notes - TheFly
- 5 weeks ago - Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants - Business Wire
- 6 weeks ago - Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright - TheFly